Update shared on 29 Oct 2025
Narrative Update on Rubicon Organics
Analysts have maintained their fair value price target for Rubicon Organics at $1.15. Recent reassessments indicate minimal changes to underlying growth and profitability assumptions.
What's in the News
- Rubicon Organics has received a Health Canada license for its Cascadia facility in Hope, British Columbia. This enables cultivation, processing, and storage of cannabis (Key Developments).
- The new 47,500 square foot indoor facility is already equipped with advanced cultivation technologies (Key Developments).
- The Cascadia facility will add 4,500kg of production capacity, increasing total annual capacity by 40% to 15,500kg of premium cannabis (Key Developments).
- Operations at the Cascadia facility have started. First revenue is anticipated in the first half of 2026 (Key Developments).
Valuation Changes
- Consensus Analyst Price Target remains unchanged at CA$1.15.
- Discount Rate is steady at 5.97%.
- Revenue Growth Projection is stable at 12.85%.
- Net Profit Margin is virtually unchanged at 5.39%.
- Future P/E Ratio holds steady at 26.32x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.